๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Nanchang
Clinical trial register · China

Clinical Trials in Nanchang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Second Affiliated Hospital of Nanchang University32 AbbVie15 The First Affiliated Hospital of Nanchang University14 Sun Yat-sen University12 Jiangxi Provincial Cancer Hospital12
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Nanchang

432 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection
NCT07382375Aortic Aneurysm and Dissection
Nanjing Medical University
Not applicable
300
Beijing, Changzhou, Chengdu, Fuzhou, Guangzhou, Nanchang, Nanjing, Shanghai
2027-12-31
Not yet open
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861Obesity, Overweight
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015Idiopathic Inflammatory Myopathies
Boehringer Ingelheim
Phase 3
270
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing
2026-11-09
Not yet open
Tirofiban Combined With Aspirin in Moderate Ischemic Stroke
NCT07760922Ischemic Stroke, Acute
Xinqiao Hospital of Chongqing
Phase 4
1,168
Haikou, Jingdezhen, Jiujiang, Nanchang
2026-10-01
Not yet open
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
NCT07789184Gastric Cancer, Peritoneal Metastasis
Hua Huang, MD, PhD
Phase 3
170
Beijing, Chongqing, Zhangzhou, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang
2026-10-01
Recruiting
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
NCT07412704Arthritis, Rheumatoid
Bristol-Myers Squibb
Phase 1/2
84
Beijing, Guangzhou, Zhengzhou, Nanchang, Shanghai
2026-09-15
Not yet open
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188Lupus Nephritis
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Not yet open
A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
NCT07791758Metastatic Colorectal Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
369
Guangzhou, Guilin, Nanning, Luoyang, Nanchang, Jinan, Shanghai, Chengdu
2026-09-04
Not yet open
Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL
NCT07831395Richter Syndrome
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
23
Zhengzhou, Changsha, Nanchang, Guangzhou, Nanjing, Wuhan
2026-09-01
Not yet open
A Phase I, Single-Arm, Open-Label Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematological Malignancies
NCT07809126Hematological Malignancies
Nanjing Miracle Biotechnology Co., Ltd.
Phase 1
30
Nanchang
2026-09
Not yet open
A Clinical Study to Evaluate CHT101 Injection in Subjects With Relapsed/Refractory T-Cell and B-Cell Hematologic Malignancies
NCT07809139Hematological Malignancies
Nanjing Miracle Biotechnology Co., Ltd.
Phase 1
30
Nanchang
2026-09
Not yet open
Efficacy and Safety of Hebenrun in Patients With Type 2 Diabetes
NCT07768280Type 2 Diabetes Mellitus
Jiangxi University of Traditional Chinese Medicine
Not applicable
110
Nanchang
2026-09
Not yet open
Study of SGC001 Injection for Predicted Severe Acute Pancreatitis to Assess Safety, Tolerability and Preliminary Efficacy
NCT07803965Acute Pancreatitis
Beijing Sungen Biomedical Technology Co., Ltd
Phase 2
129
Chengdu, Guizhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo
2026-09
Not yet open
Clinical Study of CHT105 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT07811622Immune Thrombocytopenia (ITP)
Nanjing Miracle Biotechnology Co., Ltd.
Not applicable
24
Nanchang
2026-09
Not yet open
A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
NCT06970496Relapsed or Refractory B Cell Non Hodgkin Lymphoma
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Phase 1
48
Guangzhou, Nanchang, Shanghai, Wenzhou, Xi'an
2026-08-31
Not yet open
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
NCT07745257HR-positive, HER2-negative Metastatic Breast Cancer With Brain Metastases
Sun Yat-sen University
Phase 2
40
Guangzhou, Shijiazhuang, Anyang, Zhengzhou, Nanjing, Nanchang, Dalian, Chengdu
2026-08-28
Not yet open
VBC117First-in-Human Trial of VBC117 in Participants With Advanced Malignant Solid Tumors
NCT07772934Advanced Solid Tumors
VelaVigo Bio Inc
Phase 1/2
260
Zhejiang, Zhengzhou, Changsha, Nanchang, Shengyang, Shanghai, Taiyuan
2026-08-24
Not yet open
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
NCT07749924Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC)
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Not yet open
Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease
NCT07686770Kawasaki Disease
Children's Hospital of Fudan University
Phase 2/3
90
Nanchang, Shanghai
2026-08-01
Not yet open
Yanlishuang Buccal Dropping Pills for Acute Pharyngitis
NCT07761013Acute Pharyngitis
Beijing University of Chinese Medicine
Not applicable
400
Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu
2026-08-01
Recruiting
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
NCT07533708mCRPC or Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1
48
Nanchang, Naning, Nanjing, Shanghai, Xiamen
2026-07-30
Recruiting
A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis
NCT07725939Chronic Obstructive Pulmonary Disease With Chronic Bronchitis
UCB Biopharma SRL
Phase 2
402
Beijing, Chengdu, Hangzhou, Nanchang
2026-07-27
Not yet open
Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD
NCT07634367COPD (Chronic Obstructive Pulmonary Disease)
Haisco Pharmaceutical Group Co., Ltd.
Phase 3
300
Nanchang
2026-07-10
Recruiting
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
NCT07655622Non-Small-Cell Lung Cancer
Second Affiliated Hospital of Nanchang University
Phase 1/2
45
Nanchang
2026-07-03
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai
2026-07-02
Not yet open
Study on the Impact of Decolonization Treatment of Pneumocystis Jirovecii on the Frequency of Acute Exacerbation in COPD
NCT07665359Chronic Obstructive Pulmonary Disease (COPD)
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
630
Guangzhou, Wuhan, Nanchang, Shanghai, Chengdu, Hangzhou, Huzhou, Jiaxing
2026-07-01
Not yet open
Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery
NCT07229495Scoliosis; Adolescence, Pain After Surgery, Analgesia, Patient-controlled
Peking Union Medical College Hospital
Phase 4
171
Zhengzhou, Nanchang, Beijing, Shanghai
2026-07-01
Not yet open
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma
NCT07691515Intrahepatic Cholangiocarcinoma (Icc)
Zhejiang Cancer Hospital
Phase 3
140
Guangzhou, Jiangmen, Wuhan, Changsha, Ganzhou, Nanchang, Qingdao, Chengdu
2026-07
Recruiting
An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies
NCT07619287Myeloid Malignancy
BeOne Medicines
Phase 1
118
Lanzhou, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Suzhou, Nanchang, Tianjin
2026-06-23
Recruiting
Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China
NCT07593248Lung Cancer
AstraZeneca
Observational
2,000
Beijing, Chengdu, Fuzhou, Guangzhou, Nanchang, Shanghai, Shenyang, Shijiazhuang
2026-06-22
Recruiting
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
NCT07371182Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital
Not applicable
62
Hefei, Nanning, Guiyang, Zunyi, Nanchang, Xi'an, Chengdu, รœrรผmqi
2026-06-19
Not yet open
A Randomized, Multicenter, Open-label, Active-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Multiple Intravaginal Doses of GenSci142 in Patients With Bacterial Vaginosis (BV)
NCT07663838Randomized, Open-label, Safety, Tolerability
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
30
Beijing, Nanjing, Nanchang, Changchun, Jinan, Taiyuan, Tianjin
2026-06-15
Recruiting
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
NCT07652658Idiopathic Pulmonary Fibrosis (IPF)
AstraZeneca
Phase 2
359
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Lanzhou, Nanchang, Nanjing
2026-06-11
Recruiting
Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT07668557Acute Myeloid Leukemia (AML)
iCell Gene Therapeutics
Phase 1
18
Nanchang
2026-06-10
Not yet open
Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL๏ผšStop Trial 2.0
NCT07682415CLL / SLL
Yi Shuhua
Phase 2
60
Shenzhen, Zhengzhou, Changsha, Nanjing, Nanchang, Jinan, Tianjin
2026-06-08
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
Janssen Research & Development, LLC
Phase 3
700
Beijing, Changchun, Chaoyang District, Chengdu, Guangzhou, Nanchang, Shenzhen, Tianjin
2026-05-31
Recruiting
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
NCT07463521Ocular Myasthenia Gravis
UCB Biopharma SRL
Phase 3
120
Beijing, Chengdu, Nanchang, Suzhou
2026-05-27
Not yet open
Deep Sedation vs. General Anesthesia for Pulsed Field Ablation in Atrial Fibrillation
NCT07621432Atrial Fibrillation (AF)
Second Affiliated Hospital of Nanchang University
Not applicable
80
Nanchang
2026-05-25
Not yet open
Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC
NCT07596134Unresectable Hepatocellular Carcinoma (HCC)
Zhejiang University
Not applicable
166
Kaifeng, Nanchang, Hangzhou, Yiwu
2026-05-25
Not yet open
A Single-Arm, Open-Label Phase Ia/Ib Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of FS-207 in Patients With Advanced Solid Tumors With High Microsatellite Instability (MSI-H)
NCT07593144Advanced Solid Tumors
Foresight Therapeutics (Hefei) Co., Ltd.
Phase 1
156
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanchang, Changchun
2026-05-15
Recruiting
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
NCT07607275Hypertension, Essential (Primary) Hypertension
Beijing Anzhen Hospital
Phase 4
350
Beijing, Chongqing, Dalian, Hohhot, Longyan, Luohe, Nanchang, Nanjing
2026-05-15
Recruiting
Dymista in Chinese Adolescents
NCT07597473Allergic Rhinitis Due to Allergens
Viatris Inc.
Phase 4
100
Beijing, Changsha, Chengdu, Dalian, Hangzhou, Nanchang, Shanghai, Taiyuan
2026-05-08
Recruiting
A Clinical Study of Cizutamig in Thyroid Eye Disease
NCT07597200Thyroid Eye Disease, TED
Candid Therapeutics
Phase 1
38
Hefei, Beijing, Fuzhou, Foshan, Guangzhou, Changsha, Wuhan, Nanchang
2026-05-08
Recruiting
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
NCT07415031Solid Tumors
Mirati Therapeutics Inc.
Phase 2
170
Beijing, Xiamen, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang, Jinan
2026-05-06
Recruiting
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
NCT07587099Coronary Heart Disease (CHD)
Gan Lijun
Not applicable
2,170
Beijing, Haikou, Harbin, Nanchang, Heze, Jinan, Jining, Liaocheng
2026-05-04
Not yet open
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis
NCT07566065Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
150
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Jinan, Qingdao
2026-04-30
Not yet open
Iparomlimab and Tuvonralimab Combined With SFRT and Definitive Chemoradiotherapy in Locoregionally Advanced Bulky HNSCC
NCT07041788Cancer
Second Affiliated Hospital of Nanchang University
Phase 2
25
Nanchang
2026-04-28
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
Merck Sharp & Dohme LLC
Phase 3
590
Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang
2026-04-23
Recruiting
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
NCT07365995Metastatic Castration-resistant Prostate Cancer
BioNTech SE
Phase 3
736
Changsha, Chongqing, Hangzhou, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan
2026-04-22
Not yet open
A Exploratory Study on Untreated Follicular Lymphoma With Orelabrutinib, Tafasitamab, and Lenalidomide
NCT07585747Follicular Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
27
Shenzhen, Zhengzhou, Nanchang, Jinan, Tianjin
2026-04-15
Active, closed
Thymus Dosimetric and Morphologic Predictors of Radiation-Induced Lymphopenia in Stage III NSCLC
NCT07564089Radiation-induced Lymphopenia, Thymus Dosimetric, Number of Lymphocytes
You Peimeng
Observational
450
Nanchang
2026-04-10
Recruiting
Topical Chlorhexidine Spray for the Prevention of Acute Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma:
NCT07559877Nasopharangeal Cancer
Jiangxi Provincial Cancer Hospital
Phase 3
148
Nanchang
2026-04-01
Not yet open
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan
2026-03-31
Recruiting
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NCT07493265Narcolepsy
Eisai Inc.
Phase 2
64
Beijing, Changchun, Guangdong, Guangzhou, Jinan, Nanchang, Shanghai, Zhengzhou
2026-03-26
Not yet open
Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis Due to House Dust Mites
NCT07475715Allergic Rhinitis Due to Dust Mite
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
Phase 2
250
Hefei, Nanning, Haikou, Jingzhou, Wuhan, Changsha, Hengyang, Nanchang
2026-03-23
Recruiting
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
NCT07355296Proteinuric Kidney Diseases
Boehringer Ingelheim
Phase 2
132
Beijing, Chengdu, Guangzhou, Nanchang, Nanjing, Nanning, Shanghai, Sichuan
2026-03-23
Recruiting
A Study to Investigate the Clinical Outcome and Quality of Life in Chinese Post-operative CRSwNP Patients
NCT07446738Chronic Rhinosinusitis With Nasal Polyps
AstraZeneca
Observational
200
Changchun, Changsha, Chengdu, Guangzhou, Haikou, Kunming, Nanchang, Nanjing
2026-03-19
Recruiting
HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
NCT07402239Heart Failure
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
Active, closed
Pilot Feasibility Study of a Fall Prevention Exercise Programme for Community-dwelling Older Adults in Nanchang, China
NCT07341802Fall Prevention
University of Malaya
Not applicable
36
Nanchang
2026-03-16
Recruiting
Targeted Temperature Management Via Bladder Monitoring in ICH
NCT07302009Intracerebral Hemorrhage, Targeted Temperature Management
Yanyan Gong
Not applicable
318
Nanchang
2026-03-15
Recruiting
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
NCT07412470Kidney Transplant Rejection
Sanofi
Phase 2/3
526
Beijing, Chengdu, Guangzhou, Hangzhou, Jinan, Nanchang, Nanning, Shanghai
2026-03-13
Recruiting
Effect of EIT-guided PEEP in ARDS Patients
NCT06990477ARDS (Acute Respiratory Distress Syndrome)
Southeast University, China
Not applicable
2,400
Hefei, Shanghai, Guangzhou, Zhengzhou, Hangzhou, Nanjing, Xuzhou, Nanchang
2026-03-13
Not yet open
Accelerated LBBP for Patients With RHF and Severe TR
NCT07470047Right Heart Failure
Shanghai Zhongshan Hospital
Not applicable
24
Nanchang, Shanghai
2026-03-10
Recruiting
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
NCT06951646Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT07218341Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Eli Lilly and Company
Phase 4
150
Beijing, Changsha, Guangdong, Guangzhou, Lanzhou, Nanchang, Shanghai, Taizhou
2026-03-09
Recruiting
A Study of DXC014 in Patients With Advanced Solid Tumors.
NCT07177937Small Cell Lung Cancer, Melanoma, Prostate Cancer, Other Advanced Solid Tumors
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
150
Beijing, Changsha, Nanchang, Qingdao, Hangzhou
2026-03-03
Not yet open
Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
NCT07347626Acute Ischemic Stroke
Xinqiao Hospital of Chongqing
Phase 3
786
Chongqing, Haikou, Ganzhou, Jiโ€™an, Nanchang
2026-03-01
Recruiting
Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)
NCT07352891Heart Failure With Reduced Ejection Fraction
Beijing Anzhen Hospital
Not applicable
252
Beijing, Dalian, Jilin City, Nanchang, Shanghai
2026-02-26
Recruiting
Digital Remote Management for Care and Continuous Optimization Versus Usual Care to Reduce Risk of Atherosclerotic Cardiovascular Diseases (DigiCare-preASCVD)
NCT07332468Atherosclerotic Cardiovascular Diseases
Beijing Anzhen Hospital
Not applicable
564
Beijing, Changchun, Dalian, Nanchang, Shanghai
2026-02-25
Recruiting
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
NCT07391657Relapsed Refractory Multiple Myeloma
AstraZeneca
Phase 3
508
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hefei, Nanchang, Nanjing
2026-02-23
Recruiting
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
NCT07398599Leptomeningeal Metastasis, Lung Neoplasms, Non-Small Cell Lung Cancer
Second Affiliated Hospital of Nanchang University
Not applicable
30
Nanchang
2026-02-15
Recruiting
A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors.
NCT07414316Advanced Solid Tumors
Beijing Geekgene Technology Co., LTD
Phase EARLY_PHASE1
10
Nanchang
2026-02-13
Not yet open
To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT07406438Neovascular Age-Related Macular Degeneration (nAMD)
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 1
48
Beijing, Guiyang, Zhengzhou, Nanchang, Hangzhou
2026-02-12
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
NCT07321886Obesity, Overweight
Eli Lilly and Company
Phase 3
1,980
Beijing, Chengdu, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang, Nanjing
2026-02-06
Recruiting
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
NCT07227597Small Cell Lung Cancer Extensive Stage
Merck Sharp & Dohme LLC
Phase 1/2
170
Beijing, Fuzhou, Guangzhou, Jiangmen, Nanchang, Shanghai, Chengdu, Hangzhou
2026-01-29
Recruiting
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
NCT07331272Systemic Lupus Erythematosus (SLE), Idiopathic Inflammatory Myopathies(IIM)
Nanjing Legend Biotech Co.
Phase 1
38
Bengbu, Guangzhou, Changsha, Xuzhou, Nanchang
2026-01-29
Recruiting
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525Oral Tongue Squamous Cell Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Active, closed
A Study to Evaluate the Safety,Tolerability,Pharmacokinetics and Pharmacodynamics of Cenerimod in Adult Chinese Participants With Moderate-to-severe Systemic Lupus Erythematosus (SLE)
NCT07266090SLE - Systemic Lupus Erythematosus
Viatris Pharmaceuticals Co., Ltd.
Phase 2
15
Guangzhou, Shijiazhuang, Luoyang, Zhengzhou, Jiujiang, Nanchang, Beijing
2026-01-14
Not yet open
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma๏ผˆLB2505-0001๏ผ‰
NCT07399444Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Recruiting
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL
NCT07441993Marginal Zone Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Guangzhou, Zhengzhou, Wuhan, Xiangyang, Changsha, Nanjing, Nantong, Nanchang
2026-01-05
Not yet open
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT07365371Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
174
Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City
2026-01-01
Not yet open
Early Surfactant Administration at FiOโ‚‚ >0.25 Under NIPPV for RDS in Very Preterm Infants
NCT07100652Respiratory Distress Syndrome (&Amp; [Hyaline Membrane Disease])
Jiulongpo No.1 People's Hospital
Not applicable
384
Nanchang
2026-01-01
Not yet open
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
NCT07328919Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma
TransThera Sciences (Nanjing), Inc.
Phase 3
138
Hefei, Fuzhou, Guangzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2026-01
Recruiting
A Study Evaluating the Efficacy and Safety of ABP1011T Tablets in Patients With Advanced Solid Tumors
NCT07321574SCLC, Extensive Stage, Advanced Solid Tumors
Shanghai AB PharmaTech Ltd.
Phase 2
110
Luoyang, Nanyang, Nanchang, Liaocheng, Shanghai, Taiyuan, Neijiang
2025-12-30
Recruiting
Real-World Effectiveness of Aztreonam-Avibactam Against MBL-Producing CRE
NCT07268560Complicated Intra-Abdominal Infections, cIAIs, Hospital-acquired Pneumonia (HAP), Ventilator-Associated Pneumonia (VAP)
Sir Run Run Shaw Hospital
Observational
100
Nanchang, Hangzhou
2025-12-25
Recruiting
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
NCT07252739Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 2
140
Nanjing, Nanchang, Shanghai, Chengdu
2025-12-19
Active, closed
The Role of Trop2 in Radioactive Iodine-131 Therapy Sensitivity in Papillary Thyroid Carcinoma
NCT07314255PTC, I-131, Trop2
Jiangxi Provincial Cancer Hospital
Observational
60
Nanchang
2025-12-18
Recruiting
Clinical Trial of TQB2922 Injection (Subcutaneous Injection) in Patients With Advanced Cancers
NCT07260708Advanced Cancers
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
42
Beijing, Guangzhou, Zhengzhou, Changsha, Nanjing, Nanchang, Dalian, Jinan
2025-12-16
Not yet open
Multicenter Study on Early Arterial Changes in Prediabetic Patients Evaluated by Ultra-High-Frequency Ultrasound
NCT07271745Prediabetes
Chunyan Ma
Observational
1,740
Guangzhou, Nanning, Harbin, Jiamusi, Zhengzhou, Nanjing, Nanchang, Changchun
2025-12-15
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
NCT07282600Overweight, Obesity
Eli Lilly and Company
Phase 3
1,035
Beijing, Chengdu, Chongqing, Guangzhou, Hefei, Jinan, Luoyang Shi, Nanchang
2025-12-15
Recruiting
A Study of the Efficacy and Safety of Extracorporeal Carbon Dioxide Removal Using PrismaLung+
NCT07326215Acute Respiratory Distress Syndrome, Acute Kidney Injury
Vantive Health LLC
Not applicable
99
Beijing, Guangzhou, Shenzhen, Harbin, Nanjing, Nanchang, Shanghai, Chengdu
2025-12-11
Recruiting
Direct Visualization ERAT Versus Laparoscopic Appendectomy in Adults With Acute Uncomplicated Appendicitis
NCT07230379Acute Uncomplicated Appendicitis
Changhai Hospital
Not applicable
376
Chongqing, Guangzhou, Shenzhen, Kaifeng, Zhengzhou, Changsha, Suzhou, Nanchang
2025-12-10
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
NCT07155187Non-Small Cell Lung Cancer
AbbVie
Phase 2/3
490
Guangzhou, Nanchang, Shanghai, รœrรผmqi
2025-12-10
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679Multiple Myeloma
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
42
Chongqing, Guangzhou, Chengde, Tangshan, Nanjing, Suzhou, Nanchang, Xi'an
2025-12-09
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
Merck Sharp & Dohme LLC
Phase 2
150
Beijing, Xiamen, Guangzhou, Harbin, Wuhan, Changsha, Nanjing, Nanchang
2025-12-04
Recruiting
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
NCT06807281Atopic Dermatitis
Pfizer
Phase 3
500
Beijing, Shenzhen, Changsha, Nanchang, Hangzhou, Shanghai
2025-12-02
Active, closed
A Clinical Study Evaluating the Efficacy and Safety of CreNeuriS CNS Herbal Nutrition Capsules for Participants With Mild Depressive Disorder Comorbid With Anxiety Disorder
NCT07295444Mild Depressive Disorder Comorbid With Anxiety Disorder
Second Affiliated Hospital of Nanchang University
Not applicable
30
Nanchang
2025-11-26
Recruiting
Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
NCT07160608Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Alexion Pharmaceuticals, Inc.
Phase 2
75
Baotou, Beijing, Guangzhou, Hangzhou, Nanchang, Shenzhen
2025-11-26
Recruiting
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
NCT07155174Small Cell Lung Cancer
AbbVie
Phase 2
180
Beijing, Zhengzhou, Wuhan, Nanchang, Shanghai, Chengdu
2025-11-25
Not yet open
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
NCT07240376Non-Allergic Rhinitis With Eosinophilia Syndrome
Huazhong University of Science and Technology
Not applicable
90
Guangzhou, Wuhan, Xiangyang, Nanchang, Chengdu, Beijing, Shanghai
2025-11-25
Rows per page Showing 1–100 of 432
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/nanchang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 432 of those studies with a site in Nanchang.

How many clinical trials are recruiting in Nanchang?

272 of the 432 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 57 have not yet opened recruitment, 94 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Nanchang), 432 studies
PhaseStudiesRecruitingShare
Phase 31126125.9%
Phase 2805618.5%
Not applicable734316.9%
Phase 1544112.5%
Observational503011.6%
Phase 1/232257.4%
Phase 41683.7%
Phase 2/31162.5%
Phase EARLY_PHASE1420.9%

Most active sponsors

Lead sponsors with the most studies (Nanchang)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Nanchang University3222
AbbVie157
The First Affiliated Hospital of Nanchang University1411
Jiangxi Provincial Cancer Hospital128
Sun Yat-sen University129
Sanofi113
Hoffmann-La Roche104
Merck Sharp & Dohme LLC108
Pfizer1010
Novartis Pharmaceuticals94
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.